Telcon Inc Asset Resilience Ratio
Telcon Inc asset resilience ratio. Telcon Inc (200230) has an Asset Resilience Ratio of 15.21% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 200230 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Telcon Inc (2013–2025)
Asset resilience ratio of Telcon Inc from 2013 to 2025. This chart shows how Telcon Inc's Asset Resilience Ratio has changed over time. Read 200230 liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Telcon Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Telcon Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩22.88 Billion | 15.21% |
| Total Liquid Assets | ₩22.88 Billion | 15.21% |
Asset Resilience Insights
- Good Liquidity Position: Telcon Inc maintains a healthy 15.21% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Telcon Inc Industry Peers by Asset Resilience Ratio
Compare Telcon Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
H Lundbeck A/S
CO:HLUN-B |
Drug Manufacturers - Specialty & Generic | -0.56% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Viyash Scientific Limited
NSE:SEQUENT |
Drug Manufacturers - Specialty & Generic | 0.08% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
Telcon Inc Asset Resilience Ratio by Year (2013–2025)
Telcon Inc asset resilience ratio by year from 2013 to 2025. The table below shows the annual Asset Resilience Ratio data for Telcon Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 3.83% | ₩6.00 Billion ≈ $4.07 Million |
₩156.67 Billion ≈ $106.17 Million |
-0.55pp |
| 2024-12-31 | 4.38% | ₩6.73 Billion ≈ $4.56 Million |
₩153.59 Billion ≈ $104.08 Million |
-3.10pp |
| 2023-12-31 | 7.49% | ₩10.51 Billion ≈ $7.12 Million |
₩140.41 Billion ≈ $95.16 Million |
-2.54pp |
| 2022-12-31 | 10.03% | ₩11.96 Billion ≈ $8.10 Million |
₩119.25 Billion ≈ $80.82 Million |
-3.77pp |
| 2021-12-31 | 13.80% | ₩23.19 Billion ≈ $15.72 Million |
₩168.03 Billion ≈ $113.87 Million |
+0.44pp |
| 2020-12-31 | 13.36% | ₩24.73 Billion ≈ $16.76 Million |
₩185.05 Billion ≈ $125.41 Million |
+1.30pp |
| 2019-12-31 | 12.07% | ₩15.88 Billion ≈ $10.76 Million |
₩131.65 Billion ≈ $89.22 Million |
+8.01pp |
| 2018-12-31 | 4.05% | ₩7.36 Billion ≈ $4.99 Million |
₩181.79 Billion ≈ $123.20 Million |
-10.25pp |
| 2017-12-31 | 14.30% | ₩29.98 Billion ≈ $20.32 Million |
₩209.64 Billion ≈ $142.07 Million |
+5.58pp |
| 2016-12-31 | 8.72% | ₩10.86 Billion ≈ $7.36 Million |
₩124.51 Billion ≈ $84.38 Million |
+8.62pp |
| 2015-12-31 | 0.10% | ₩50.00 Million ≈ $33.88K |
₩48.15 Billion ≈ $32.63 Million |
-12.87pp |
| 2014-12-31 | 12.97% | ₩6.20 Billion ≈ $4.20 Million |
₩47.76 Billion ≈ $32.37 Million |
+6.27pp |
| 2013-12-31 | 6.71% | ₩2.16 Billion ≈ $1.46 Million |
₩32.20 Billion ≈ $21.82 Million |
-- |
About Telcon Inc
TELCON RF PHARMACEUTICAL. Inc. primarily engages in the development, production, and sale of RF coaxial connectors worldwide. It also provides coaxial couplers, distributors, and arresters, as well as cable assemblies; and pharmaceuticals. The company was formerly known as Telcon Co., Ltd. TELCON RF PHARMACEUTICAL. Inc. was founded in 1999 and is headquartered in Yongin-si, South Korea.